SCHEMBL286031

SCHEMBL286031

O=C(O)C(Cc1ccc(O)cc1)NS(=O)(=O)O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
FOLH1 Q04609 1/20 0.52
NAALAD2 Q9Y3Q0 1/20 0.52
MMP2 P08253 4/20 0.50
MMP9 P14780 3/20 0.50
SLC7A5 Q01650 1/20 0.50
ADAMTS4 O75173 1/20 0.50
MME P08473 2/20 0.49
ENPEP Q07075 2/20 0.48
ACE P12821 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CPA1 P15085 1/20 0.48
ACE2 Q9BYF1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286032 1.00 MEN1 (0.63) MEN1KMT2AL3MBTL1CA1CA2
Chloroform SCHEMBL28104113 0.95 MEN1 (0.59) MEN1KMT2AL3MBTL1CA1CA2
SCHEMBL7297540 0.86 MMP2 (0.65) CA1CA2NAALAD2MMP2MMP9
SCHEMBL7297543 0.86 MMP2 (0.65) CA1CA2NAALAD2MMP2MMP9
SCHEMBL17318156 0.85 L3MBTL1 (0.62) MEN1KMT2AL3MBTL1CA1CA2
SCHEMBL17318080 0.85 L3MBTL1 (0.62) MEN1KMT2AL3MBTL1CA1CA2
SCHEMBL3266667 0.84 MEN1 (0.60) MEN1KMT2AL3MBTL1CA1CA2
SCHEMBL28396545 0.84 L3MBTL1 (0.64) MEN1KMT2AL3MBTL1CA1CA2
SCHEMBL8912956 0.81 L3MBTL1 (0.78) MEN1KMT2AL3MBTL1MMP2MMP9
SCHEMBL17111996 0.81 ITGB3 (0.49) MEN1KMT2AL3MBTL1CA2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195327-A1 METHOD FOR PREVENTING OR LIMITING PROGRESSION OF MYOPIA CATALTHEIA GROUP, INC. (US) 2025-06-19 US claimed
US-20210294125-A1 SOFT CONTACT LENS BF RESEARCH S.R.L. (IT) 2021-09-23 US claimed
EP-3797333-A1 SOFT CONTACT LENS BF Research S.r.L. (IT) 2021-03-31 EP claimed
CN-106146360-B Method for preparing tyrosine-O-sulfonate 深圳翰宇药业股份有限公司 2020-05-15 CN claimed
EP-3383883-A1 SALTS OF CONJUGATES FOR CANCER THERAPY BioSight Ltd. (IL) 2018-10-10 EP claimed
WO-2017094011-A1 SALTS OF CONJUGATES FOR CANCER THERAPY BIOSIGHT LTD. (IL) 2017-06-08 WO claimed
CN-106146360-A A kind of method preparing tyrosine-O-sulfonate 深圳翰宇药业股份有限公司 2016-11-23 CN claimed
EP-1411964-A4 PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF OREGON HEALTH SCIENCE UNIVERSI (US) 2006-06-14 EP claimed
US-20040248807-A1 Peptides which modulate blood coagulation and methods of use thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-12-09 US claimed
EP-1411964-A2 PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF OREGON HEALTH SCIENCE UNIVERSITY (US) 2004-04-28 EP claimed
WO-2003003988-A2 PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF OREGON HEALTH & SCIENCE UNIVERSITY (US) 2003-01-16 WO claimed
US-20250195327-A1 METHOD FOR PREVENTING OR LIMITING PROGRESSION OF MYOPIA CATALTHEIA GROUP, INC. (US) 2025-06-19 US disclosed
US-20250145668-A1 EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION CENTIVAX, INC. 2025-05-08 US disclosed
CN-116338052-B High performance liquid chromatography analysis method for O-sulfo-L-tyrosine sodium salt and related substances thereof 安徽盈科生物科技有限公司 2025-05-02 CN disclosed
US-12268652-B2 Method for preventing or limiting progression of myopia CATALTHEIA GROUP, INC. (US) 2025-04-08 US disclosed
US-6548636-B2 Composition for use as viricide in prevention of viral infection PROGENICS PHARMACEUTICALS, INC. 2003-04-15 US disclosed
WO-2003003988-A2 PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF OREGON HEALTH & SCIENCE UNIVERSITY (US) 2003-01-16 WO disclosed
WO-2002068608-A2 SULFATED CCR5 PEPTIDES FOR HIV-1 INFECTION PROGENICS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed
US-20020068813-A1 Sulfated CCR5 peptides for HIV-1 infection AARON DIAMOND AIDS RESEARCH CENTRE (ADARC) 2002-06-06 US disclosed
WO-2001064710-A2 SULFATED CCR5 PEPTIDES FOR HIV-1 INFECTION PROGENICS PHARMACEUTICALS, INC. (US) 2001-09-07 WO disclosed